DBV.PA stock opens pre-market under close scrutiny as DBV Technologies advances two Biologics License Application (BLA) filings for VIASKIN Peanut and prepares an earnings update on 23 Mar 2026. Investors will watch regulatory timing, cash runway and commercial readiness from France-listed DBV Technologies on Euronext. At €3.45 with daily range €3.42–€3.54 and volume 487881.00, the company’s clinical results and launch commentary are the main drivers before the report.
Earnings setup for DBV.PA stock
DBV.PA stock reports earnings on 23 Mar 2026, a pre-market catalyst for shares ahead of planned BLA actions. The earnings date ties directly to management’s public BLA timeline statements and any updated guidance.
The current quote shows Price €3.45, Market Cap €583,384,139.00, EPS -0.91 and PE -3.79, so the release will be read for cash burn, R&D pacing and clarity on U.S. filing windows.
Clinical and commercial catalysts driving DBV.PA stock
Management plans separate BLAs for ages 4–7 and 1–3 for VIASKIN Peanut, creating two regulatory opportunities that could shape revenue timing and label scope. Recent presentations highlighted a 47% responder rate in VITESSE versus 15% placebo and longer-term open-label gains, which investors will parse for commercial potential (source: MarketBeat).
DBV’s rollout strategy targets allergists first and pediatricians second, with pricing work ongoing and a stated pro forma cash runway of about €300,000,000.00 to cover U.S. launch preparation. For broader context on market quotes and sentiment see CNBC.
Financials and valuation: hard numbers for DBV.PA stock
DBV.PA stock shows research intensity and negative earnings: Revenue per share €0.01, Net income per share -€1.30, Cash per share €0.73, and Price/Book 7.24. The company is operating at scale in R&D with R&D to revenue ~79.82%, which explains large losses and a negative PE.
Liquidity indicators matter: Shares outstanding 169,096,852.00, Avg Volume 1,534,261.00, and Relative Volume 0.37 show trading is thinner on low-volume days. Investors should compare these ratios to the Healthcare/Biotech sector where average PE and PB are higher and profitability metrics vary.
Technical picture and trading context for DBV.PA stock
Short-term indicators point to consolidation: RSI 42.13 and ADX 15.49 indicate no strong trend, while Bollinger Bands sit €3.37–€4.04. Volume today at 487,881.00 is below the average, limiting conviction ahead of earnings.
Technicals imply range trading until a catalyst forces a breakout; watch for a move above the 50-day average €3.66 for momentum or a drop below €3.37 to test support.
Meyka AI rates DBV.PA with a score out of 100 and forecast
Meyka AI rates DBV.PA with a score of 67.23 out of 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 12‑month price of €4.16, a quarterly target €4.91, and a monthly signal at €4.31. Versus the current €3.45, the model implies a 12‑month upside of 20.66% and a near-term upside to the quarterly target of 42.32%. Forecasts are model-based projections and not guarantees.
Risks and opportunities shaping DBV.PA stock
The primary opportunity is U.S. approval and a practical, at‑home patch therapy addressing an unmet need in pediatric peanut allergy; successful BLAs could drive commercial value and re-rate the shares.
Key risks include regulatory delays, label restrictions, disappointing launch economics, and cash burn if commercial ramp costs exceed expectations. Watch milestone timing, COMFORT study completion, and cash balance disclosures closely.
Final Thoughts
DBV.PA stock sits at a clinical inflection point heading into the 23 Mar 2026 earnings release. The market will treat the report as a readout on cash runway, BLA timing and commercial readiness for VIASKIN Peanut. With the share price at €3.45 and market cap €583,384,139.00, DBV blends high clinical upside and binary regulatory risk. Meyka AI’s model projects a 12‑month price of €4.16, implying +20.66% from today, while a near-term operational push could reach the quarterly model level of €4.91. Our grade is B (HOLD), reflecting strong platform potential offset by current losses and execution risk. Use earnings detail to reassess conviction: clarity on BLA submissions, COMFORT study timing and cash guidance will matter most. For a quick company snapshot and live quotes, see our Meyka AI market page for DBV.PA and the linked news sources.
FAQs
When does DBV.PA stock report earnings and why does it matter?
DBV.PA stock reports earnings on 23 Mar 2026 and investors will use the release to check cash runway, BLA timelines for VIASKIN Peanut, and guidance that can change near-term valuation.
What is Meyka AI’s view and grade for DBV.PA stock?
Meyka AI rates DBV.PA 67.23/100, Grade B (HOLD). The grade combines sector comparison, financial growth, key metrics, and analyst signals; it is informational, not a recommendation.
What price targets and forecast exist for DBV.PA stock?
Meyka AI’s forecast model projects €4.16 in 12 months (implied +20.66%) and a near-term quarterly level of €4.91. These are model projections and not guarantees.
What are the main risks investors should watch for DBV.PA stock?
Key risks for DBV.PA stock include regulatory delays on BLAs, less favorable label or pricing, higher-than-expected commercial costs, and cash burn that could force dilution or slower launches.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)